ViiV Healthcare announces US FDA approval of Apretude ... - GSK
2021年12月20日 · Apretude is the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option proven superior to daily oral FTC/TDF in reducing HIV acquisition. It is indicated for HIV PrEP in adults and adolescents at risk of sexually acquiring HIV, weighing at least 35 kg, who have a negative HIV-1 test prior to initiation.
Resources for healthcare providers - apretudehcp.com
APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.
ViiV Healthcare shows more than 99% effectiveness in real-world ... - GSK
2024年10月16日 · Apretude is a medicine used for preventing sexually transmitted HIV-1 infection (pre-exposure prophylaxis or PrEP) in adults and adolescents weighing at least 35 kg who are at high risk of being infected. It should be used in combination with safer sex practices, such as …
Long-acting PrEP | APRETUDE (cabotegravir)
APRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg). APRETUDE is administered as an intramuscular injection by a healthcare professional every 2 months after 2 initiation injections administered 1 month apart.
ViiV Healthcare’s cabotegravir for HIV prevention receives ... - GSK
2023年7月24日 · Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kg.
Issued: London, UK - us.gsk.com
2024年10月16日 · APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP.
ViiV Healthcare to present first head-to-head data for long ... - GSK
2023年2月14日 · APRETUDE (cabotegravir) extended-release injectable suspensions. INDICATION. APRETUDE is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
Apretude (cabotegravir) 用于治疗 HIV-1 暴露前预防 (PrEP)
Apretude (cabotegravir) 是首个也是唯一一个可注射的长效暴露前预防 (PrEP) 治疗，可将性获得性HIV-1风险降至最低。 该药物由葛兰素史克（GSK）、辉瑞和 Shionogi 的合资企业 ViiV Healthcare 开发。
ViiV Healthcare announces US FDA approval of Apretude ... - GSK
2021年12月20日 · Apretude is the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option proven superior to daily oral FTC/TDF in reducing HIV acquisition. It is indicated for HIV PrEP in adults and adolescents at risk of sexually acquiring HIV, weighing at least 35 kg, who have a negative HIV-1 test prior to initiation.
FDA approves injectable form of GSK HIV prevention drug
2021年12月20日 · The injection - Apretude - to prevent the virus that causes AIDS is aimed as an alternative to daily pills and has been approved for use in at-risk adults and adolescents.